Overview

Study of Transitioning From Alendronate to Denosumab

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab. Endpoints studied will include bone mineral density, bone turnover markers and bone histology in a subset of subjects.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Alendronate
Denosumab